Pulmonologist Dr. Edmund Moon on Mesothelioma ImmunotherapyTreatment & Doctors
Written by Dr. Edmund K. Moon
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family.LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
Moon, E. K. (2022, April 12). Pulmonologist Dr. Edmund Moon on Mesothelioma Immunotherapy. Asbestos.com. Retrieved December 6, 2023, from https://www.asbestos.com/blog/2021/06/17/edmund-moon-mesothelioma-immunotherapy/
Moon, Edmund K. "Pulmonologist Dr. Edmund Moon on Mesothelioma Immunotherapy." Asbestos.com, 12 Apr 2022, https://www.asbestos.com/blog/2021/06/17/edmund-moon-mesothelioma-immunotherapy/.
Moon, Edmund K. "Pulmonologist Dr. Edmund Moon on Mesothelioma Immunotherapy." Asbestos.com. Last modified April 12, 2022. https://www.asbestos.com/blog/2021/06/17/edmund-moon-mesothelioma-immunotherapy/.
In recent years, it has become increasingly clear that immunotherapy may be the most crucial advancement in cancer research perhaps ever.
Early in my medical career, I was not initially interested in cancer research. During my interventional pulmonary fellowship training at the University of Pennsylvania, I developed a meaningful and productive partnership with the thoracic oncology research lab.
Simultaneously, a new T-cell immunotherapy initiative at UPenn was gaining popularity. It was the perfect time to transition into a cancer research career. Looking ahead, I am excited about the potential of immunotherapy and how it can change the course of mesothelioma treatment.
Recent Immunotherapy Research Shows Promise
Historically, T-cell immunotherapy has proven to be very successful in treating hematologic cancers such as leukemia. When adopting the technology for solid cancers, such as lung cancer and mesothelioma, overcoming certain obstacles requires us to develop novel approaches.
One of the first steps in this process is characterizing the tumor microenvironment. In other words, we must identify how tumor cells interact with our body and immune system. This area is one of my primary areas of research.
In 2019, I published several papers on the role of unique T-cell variants, immune cells that help fight infection. When modified in a laboratory, scientists can program these cells to identify cancer targets such as mesothelin, a protein present on mesothelioma cells.
Earlier this year, my colleagues and I published research on why some lung cancer patients may not respond to T-cell immunotherapy. Immune checkpoint treatment relies on removing the blocks that prevent T cells from identifying and attacking solid tumors. This has worked in certain settings. However, in many cases, tumor cells can defend themselves by compensating with other inhibitory molecules.
Our research discovered that combining therapies that blocked PD1 and TIM3 checkpoints resulted in greater tumor control than inhibiting PD1 alone. These results will help lead to more discoveries of the optimal combination of immunotherapies for mesothelioma patients.
There is still much we need to learn about our immune system and how it interacts with different cancers, but identifying potential new treatments is one of the most exciting parts of my research career.
Benefits of Immunotherapy for Mesothelioma Patients
Many cancer patients are choosing immunotherapy as part of their multimodal treatment plan. Clinical trials have shown that these drugs successfully boost the immune system to shrink tumors and prevent regrowth.
The U.S. Food and Drug Administration has approved two immune checkpoint inhibitor therapies for mesothelioma patients. The first, Keytruda, also known as pembrolizumab, has been a valuable option for lung cancer patients and is now available as a second-line treatment for mesothelioma patients.
The second option, approved in October 2020, is a combination therapy of Opdivo and Yervoy, known as nivolumab and ipilimumab, respectively. The FDA previously approved this treatment as first-line therapy for metastatic non-small cell lung cancer. This type of combination immunotherapy is key to unlocking the anti-tumor benefits of the immune system.
T cells are essential for identifying and destroying tumor cells. Opdivo works by helping T cells discover the mesothelioma tumor, and Yervoy activates and proliferates T cells so that there is enough in the circulating blood.
An experimental approach in engineering T cells against cancer is CAR T-cell therapy. It is a type of adoptive cell transfer, an area of my work that involves genetically modifying receptors on the surface of T cells. We can manipulate those receptors to “see” and connect with antigen proteins specific to the cancers in individual patients.
We replicate these T cells in a lab and then deliver them back to the patient. The initial results for mesothelioma are promising, but more research is needed to find the best targets on the surface of solid tumors.
Overall, immunotherapy is a critical new treatment method for mesothelioma patients, and I am excited to be a part of its future. Working with an energetic and internationally renowned team at UPenn has been a motivational experience. As research continues in this promising new field, I expect we will soon see unprecedented advances against this terrible disease.